#### Edgar Filing: China Biologic Products, Inc. - Form 4

China Biolo Form 4 March 02, 2	ogic Products, Inc	2.										
Check ti if no lor subject Section Form 4	<b>A</b> 4 UNITED	Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES								PROVAL 3235-0287 January 31, 2005 verage rs per 0.5		
Form 5 obligation may con <i>See</i> Inst 1(b).	ons ntinue. Section 17	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section										
(Print or Type	Responses)											
1. Name and Address of Reporting Person *2. IGao DavidSymbol				er Name <b>an</b>	<b>d</b> Ticker or	Tradii	-8	5. Relationship of Reporting Person(s) to Issuer				
		China Biologic Products, Inc. [CBPO]					(Check all applicable)					
18TH FLOOR, JIALONG 02 INTERNATIONAL, BUILDING, 19			3. Date of Earliest Transaction (Month/Day/Year) 02/28/2017				-	_X_ Director10% Owner _X_ Officer (give titleOther (specify below) below) Chief Executive Officer				
CHAOYANG PARK ROAD (Street) 4. If Amendment, Date Original 6. Individual or Joi								int/Group Filing(Check				
· / / ·····				onth/Day/Year)				Applicable Line) _X_ Form filed by One Reporting Person				
BEIJING, F4 100125								Form filed by More than One Reporting Person				
(City)	(State)	(Zip)	Tab	le I - Non-J	Derivative	Secur	ities Acqu	ired, Disposed of,	or Beneficial	ly Owned		
1.Title of Security (Instr. 3)	Security (Month/Day/Year) Execution Date, if			3. 4. Securities Acquired (A Transaction Disposed of (D) Code (Instr. 3, 4 and 5) (Instr. 8) (A)				Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code V	Amount	or (D)	Price	Transaction(s) (Instr. 3 and 4)	(Instr. 4)			
Common Stock	02/28/2017			S <u>(1)</u>	62,604 (1)	D	\$ 100.69 (3)	449,396	D			
Common Stock	03/01/2017			S <u>(1)</u>	54,049 (2)	D	\$ 100.57 (4)	395,347	D			

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of<br/>information contained in this form are not<br/>required to respond unless the formSEC 1474<br/>(9-02)

#### Edgar Filing: China Biologic Products, Inc. - Form 4

# displays a currently valid OMB control number.

## Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transact Code (Instr. 8)	5. ionNumber of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	;	Date	Secur	int of rlying	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secu Bene Owne Follo Repo Trans (Instr
				Code V	7 (A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

### **Reporting Owners**

<b>Reporting Owner Name / Address</b>	Relationships					
	Director	10% Owner	Officer	Other		
Gao David 18TH FLOOR, JIALONG INTERNATIONAL BUILDING, 19 CHAOYANG PARK ROAD BEIJING, F4 100125	Х		Chief Executive Officer			

## **Signatures**

/s/ David (Xiaoying) Gao 03/02/2017

\*\*Signature of Reporting Person

## **Explanation of Responses:**

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

Date

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Represents 62,604 shares of common stock sold in the open market at a weighted average price of \$100.69 per share on Februray 28,
 (1) 2017. The Reporting Person intends to use the proceeds from the sale to pay income tax due in connection with the scheduled vesting of certain restricted stock held by the Reporting Person and the exercise of certain stock options held by the Reporting Person.

Represents 54,049 shares of common stock sold in the open market at a weighted average price of \$100.57 per share on March 1, 2017.
 (2) The Reporting Person intends to use the proceeds from the sale to pay income tax due in connection with the scheduled vesting of certain restricted stock held by the Reporting Person and the exercise of certain stock options held by the Reporting Person.

- (3) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in the open market at prices ranging from \$99.04 to \$104.48, inclusive.\*
- (4) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in the open market at prices ranging from \$100.00 to \$102.57, inclusive.\*

#### **Remarks:**

\* The Reporting Person undertakes to provide to any security holders of the Issuer or the staff of the Commission, upon reques

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.